Key Takeaways:
- Pfizer offers a substantial dividend yield of 7.5%, significantly surpassing the S&P 500 average.
- Analysts' average price target suggests a notable upside potential of 38.67% from the current stock price.
- GuruFocus estimates suggest a promising GF Value upside of 31.32%, highlighting the stock's potential for growth.
Pfizer Inc (PFE, Financial) remains an enticing choice for dividend-focused investors, boasting a remarkable yield of 7.5%. This yield is well above the typical S&P 500 average, offering a stable income stream even as the stock has faced a 16% decline this year. Despite these challenges, Pfizer is committed to achieving stability and implementing cost-saving measures to sustain its attractive dividend payouts.
Analyst Price Predictions
According to projections from 19 financial analysts, Pfizer Inc (PFE, Financial) has an average one-year price target of $30.29. These estimates range from a high of $41.43 to a low of $24.00, reflecting a potential upside of 38.67% from the current trading price of $21.84. For an in-depth view of these estimates, visit the Pfizer Inc (PFE) Forecast page.
Brokerage Recommendations
The consensus from 23 brokerage firms places Pfizer Inc's (PFE, Financial) average recommendation at 2.6, categorizing it as a "Hold." This rating scale ranges from 1 to 5, with 1 representing a Strong Buy and 5 indicating a Sell position.
GuruFocus's Valuation Insights
GuruFocus estimates the GF Value of Pfizer Inc (PFE, Financial) to be $28.68 within a year, pointing to an upside potential of 31.32% from its current price of $21.84. This valuation is based on historic trading multiples, past growth trends, and anticipated future business performance. For more comprehensive data, explore the Pfizer Inc (PFE) Summary page.
